Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Ahead Study: A 3 Year Follow-up of 522 Severe and Moderate Hemophilia a Patients

Johannes Oldenburg, Prof, Dimitrios Tsakiris, Prof, Cedric R. Hermans, MD PhD MRCP, RI Liesner, MD FRCP, FRCPath, MA, MBBChir, Kate Khair, Maria Gabriella Mazzucconi, Prof, Katharina N Steinitz-Trost, PhD, Gerald Spotts, PhD, Armin J Reininger, Prof, Alessandro Gringeri, MD MSc

Blood (2016) 128 (22): 3786.

https://doi.org/10.1182/blood.V128.22.3786.3786

Published: 2016

Journal Articles

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

Kathelijn Fischer, MD PhD MSc, Pratima Chowdary, FRCPath, MRCPath, MRCP, MD, Peter Collins, MD, Amy Cotterill, PhD, Barbara Konkle, MD, Victor S. Blanchette, FRCP, FRCPC, Steven W. Pipe, MD, Martin Wolfsegger, Cstat (RSS), Werner Engl, PhD Cstat, Jimena V Goldstine, PhD, Leonard A. Valentino, MD FAAP, Gerald Spotts, PhD

Blood (2016) 128 (22): 2576.

https://doi.org/10.1182/blood.V128.22.2576.2576

Published: 2016

Journal Articles

Validation of the rAHF-PFM PK Guided Dose Calculator Medical Device Using an Unrelated Clinical Dataset

Katharina Nora Steinitz, PhD, Gerald Spotts, PhD, Alexandra Loew-Baselli, PhD, Myungshin Oh, PhD, Mark Penny, Alessandro Gringeri, MD, Armin J Reininger, MD

Blood (2014) 124 (21): 1500.

https://doi.org/10.1182/blood.V124.21.1500.1500

Published: 2014

Journal Articles

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Gerald Spotts, PhD, Steven W. Pipe, MD, Erik Berntorp, MD PhD, Peter W. Collins, MD, Victor S. Blanchette, MD FRCPC, Kathelijn Fischer, MD PhD MSC, MyungShin Oh, Leonard A. Valentino, MD FAAP

Blood (2014) 124 (21): 689.

https://doi.org/10.1182/blood.V124.21.689.689

Published: 2014

Journal Articles

Safety and Efficacy Profile of rAHF-PFM for Immune Tolerance Induction as Assessed In 3 Clinical Trials (PUP ITI, PRE-PAIR, and PAIR).

Gerald Spotts, PhD, Brigitt E. Abbuehl, MD, Huong D. Luu, PharmD, Clara K. Song, PharmD, Jacqueline A. Dyck-Jones, Norma Guzman-Becerra, LieLing Wu, MyungShin Oh, Michael Zoerer, Judith Jill V. Sosa, Darby E. Stephens, Linda J. Yamamoto, MD, Bruce M. Ewenstein, MD, PhD

Blood (2010) 116 (21): 3670.

https://doi.org/10.1182/blood.V116.21.3670.3670

Published: 2010

Journal Articles

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Jan Astermark, MD, PhD, John Schwarz, MA, Sharyne M. Donfield, PhD, Donna M. DiMichele, MD, Bruce M. Ewenstein, MD, PhD, Edward D. Gomperts, MD, George W. Nelson, PhD, Johannes Oldenburg, MD, PhD, Amy D. Shapiro, MD, Gerald Spotts, PhD, Cheryl A. Winkler, PhD, Erik Berntorp, MD, PhD

Blood (2009) 114 (22): 217.

https://doi.org/10.1182/blood.V114.22.217.217

Published: 2009

Journal Articles

Population Pharmacokinetic Model of ADVATE in Pediatric and Adult Patients with Hemophilia A.

Myungshin Oh, PhD, Sven Björkman, PhD, Phillip Schroth, Sandor Fritsch, PhD, Peter Collins, MD, Kathelijn Fischer, MD, PhD, MSc, Victor S. Blanchette, MD, Kathleen M. Casey, PhD, Gerald Spotts, PhD, Bruce M. Ewenstein, MD, PhD

Blood (2009) 114 (22): 3492.

https://doi.org/10.1182/blood.V114.22.3492.3492

Published: 2009

Journal Articles

ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin- Free Method] Post-Authorization Safety Surveillance (PASS): Safety and Efficacy Following Product Switch in Routine Clinical Practice.

Huong Luu, PharmD, Gerald Spotts, PhD, Hartwig Gajek, MD, Alex Kriukov, Roger Berg, MD, Darby Stephens, Kerry Barker, Bruce M. Ewenstein, MD, PhD

Blood (2008) 112 (11): 3375.

https://doi.org/10.1182/blood.V112.11.3375.3375

Published: 2008

Journal Articles

Effect of Normal Variation in Factor VIII Pharmacokinetics on Prophylactic Dosing Requirements in Severe Classical Hemophilia.

Peter Collins, Kathelijn Fischer, MD, PhD, MSC, Victor S. Blanchette, FRCP, Sven Björkman, Myungshin Oh, Phillip Schroth, Kathleen M. Casey, PhD, Gerald Spotts, PhD, Sandor Fritsch, Bruce M. Ewenstein, MD, PhD

Blood (2008) 112 (11): 1222.

https://doi.org/10.1182/blood.V112.11.1222.1222

Published: 2008

Journal Articles

Internal and External Determinants of Bleeding Patterns on Prophylaxis for Severe Haemophilia A.

Kathelijn Fischer, MD, PhD, Peter Collins, MD, Jan Astermark, MD, Victor S. Blanchette, MD, Sven Bjorkman, PhD, Myungshin Oh, PhD, Phillip Schroth, Sandor Fritsch, PhD, Kathleen M. Casey, PhD, Gerald Spotts, PhD, Bruce M. Ewenstein, MD, PhD

Blood (2007) 110 (11): 1145.

https://doi.org/10.1182/blood.V110.11.1145.1145

Published: 2007

Journal Articles

Safety Profile of Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM) from Post-Authorization Safety Surveillance (PASS) Program.

Huong Luu, PharmD, Gerald Spotts, PhD, Hartwig Gajek, MD, Alex Kriukov, Roger Berg, MD, Darby Stephens, Kerry Barker, Bruce Ewenstein, MD, PhD

Blood (2007) 110 (11): 3972.

https://doi.org/10.1182/blood.V110.11.3972.3972

Published: 2007

Journal Articles

Characterization of the Pharmacokinetics of rFVIII in Young Pre-School Children with Hemophilia, Including an Analysis of the Influence of Age and Body Weight.

Victor Blanchette, MD, Amy D. Shapiro, MD, Raina Liesner, BChir, Fernando Hernandez, MD, Anastassios D. Retzios, PhD, Phillip Schroth, CStat, Sandor Fritsch, Gerald Spotts, PhD, Bruce M. Ewenstein, MD, PhD

Blood (2004) 104 (11): 3084.

https://doi.org/10.1182/blood.V104.11.3084.3084

Published: 2004

NARROW

Ahead Study: A 3 Year Follow-up of 522 Severe and Moderate Hemophilia a Patients

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

Validation of the rAHF-PFM PK Guided Dose Calculator Medical Device Using an Unrelated Clinical Dataset

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Safety and Efficacy Profile of rAHF-PFM for Immune Tolerance Induction as Assessed In 3 Clinical Trials (PUP ITI, PRE-PAIR, and PAIR).

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Population Pharmacokinetic Model of ADVATE in Pediatric and Adult Patients with Hemophilia A.

ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin- Free Method] Post-Authorization Safety Surveillance (PASS): Safety and Efficacy Following Product Switch in Routine Clinical Practice.

Effect of Normal Variation in Factor VIII Pharmacokinetics on Prophylactic Dosing Requirements in Severe Classical Hemophilia.

Internal and External Determinants of Bleeding Patterns on Prophylaxis for Severe Haemophilia A.

Safety Profile of Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM) from Post-Authorization Safety Surveillance (PASS) Program.

Characterization of the Pharmacokinetics of rFVIII in Young Pre-School Children with Hemophilia, Including an Analysis of the Influence of Age and Body Weight.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only